These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

317 related items for PubMed ID: 34529129

  • 1. Blastic plasmacytoid dendritic-cell neoplasia: a challenging case report.
    Koerber RM, Held SAE, Vonnahme M, Feldmann G, Wenzel J, Gütgemann I, Brossart P, Heine A.
    J Cancer Res Clin Oncol; 2022 Mar; 148(3):743-748. PubMed ID: 34529129
    [Abstract] [Full Text] [Related]

  • 2. Diagnostic management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in close interaction with therapeutic considerations.
    Shumilov E, Mazzeo P, Ghandili S, Künstner A, Weidemann S, Banz Y, Ströbel P, Pollak M, Kolloch L, Beltraminelli H, Kerkhoff A, Mikesch JH, Schliemann C, Haase D, Wulf G, Legros M, Lenz G, Feldmeyer L, Pabst T, Witte H, Gebauer N, Bacher U.
    Ann Hematol; 2024 May; 103(5):1587-1599. PubMed ID: 38194088
    [Abstract] [Full Text] [Related]

  • 3. Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: A case report and literature review.
    Samhouri Y, Ursu S, Dutton N, Tanvi V, Fazal S.
    J Oncol Pharm Pract; 2021 Jun; 27(4):990-995. PubMed ID: 32847479
    [Abstract] [Full Text] [Related]

  • 4. Cytologic features of blastic plasmacytoid dendritic cell neoplasm involving liver: A case report and literature review.
    Ding Y, Yang J, Lindsey K.
    Diagn Cytopathol; 2021 Feb; 49(2):E80-E83. PubMed ID: 32852895
    [Abstract] [Full Text] [Related]

  • 5. Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm (BPDCN).
    Beird HC, Khan M, Wang F, Alfayez M, Cai T, Zhao L, Khoury J, Futreal PA, Konopleva M, Pemmaraju N.
    Blood Cancer J; 2019 Dec 06; 9(12):99. PubMed ID: 31811114
    [Abstract] [Full Text] [Related]

  • 6. Role of tagraxofusp in treating blastic plasmacytoid dendritic cell neoplasm (BPDCN).
    Alfayez M, Konopleva M, Pemmaraju N.
    Expert Opin Biol Ther; 2020 Feb 06; 20(2):115-123. PubMed ID: 31801379
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Blastic Plasmacytoid Dendritic Cell Neoplasm: From Origin of the Cell to Targeted Therapies.
    Laribi K, Denizon N, Besançon A, Farhi J, Lemaire P, Sandrini J, Truong C, Ghnaya H, Baugier de Materre A.
    Biol Blood Marrow Transplant; 2016 Aug 06; 22(8):1357-1367. PubMed ID: 27026248
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Clinicopathological analysis of 46 cases with CD4+ and/or CD56+ immature haematolymphoid malignancy: reappraisal of blastic plasmacytoid dendritic cell and related neoplasms.
    Suzuki Y, Kato S, Kohno K, Satou A, Eladl AE, Asano N, Kono M, Kato Y, Taniwaki M, Akiyama M, Nakamura S.
    Histopathology; 2017 Dec 06; 71(6):972-984. PubMed ID: 28795410
    [Abstract] [Full Text] [Related]

  • 11. Blastic Plasmacytoid Dendritic Cell Neoplasm: Progress in Cell Origin, Molecular Biology, Diagnostic Criteria and Therapeutic Approaches.
    Cheng W, Yu TT, Tang AP, He Young K, Yu L.
    Curr Med Sci; 2021 Jun 06; 41(3):405-419. PubMed ID: 34218354
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations.
    Pemmaraju N, Madanat YF, Rizzieri D, Fazal S, Rampal R, Mannis G, Wang ES, Foran J, Lane AA.
    Leuk Lymphoma; 2024 May 06; 65(5):548-559. PubMed ID: 38391126
    [Abstract] [Full Text] [Related]

  • 14. Immunohistochemical analysis of CD123, CD56 and CD4 for the diagnosis of minimal bone marrow involvement by blastic plasmacytoid dendritic cell neoplasm.
    Hwang K, Park CJ, Jang S, Chi HS, Huh JR, Lee JH, Suh C, Lee KH.
    Histopathology; 2013 Apr 06; 62(5):764-70. PubMed ID: 23470050
    [Abstract] [Full Text] [Related]

  • 15. Blastic Plasmacytoid Dendritic Cell Neoplasm-Current Insights.
    Venugopal S, Zhou S, El Jamal SM, Lane AA, Mascarenhas J.
    Clin Lymphoma Myeloma Leuk; 2019 Sep 06; 19(9):545-554. PubMed ID: 31281107
    [Abstract] [Full Text] [Related]

  • 16. A blastic plasmacytoid dendritic cell neoplasm-like immunophenotype is negatively associated with CEBPA bZIP mutation and predicts unfavorable prognosis in acute myeloid leukemia.
    Song J, Li W, Bai Y, Zhou P, Niu J, Niu X, Liu Y, Liu X, Drokow EK, Sun K, Zhou H.
    Ann Hematol; 2024 Feb 06; 103(2):463-473. PubMed ID: 38183444
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Blastic plasmacytoid dendritic cell neoplasm with a history of cytopenia: A case report.
    Yan M, Wang W, Cen X, Wang L, Sun Y, Wang B, Ou J, Nong L, Ren H, Zhu P, Wang M.
    Diagn Cytopathol; 2020 Nov 06; 48(11):1102-1106. PubMed ID: 32374950
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.